Observational Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2017; 23(19): 3513-3521
Published online May 21, 2017. doi: 10.3748/wjg.v23.i19.3513
Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study
Wan-Tzu Lin, Yi-Jun Liao, Yen-Chun Peng, Chung-Hsin Chang, Ching-Heng Lin, Hong-Zen Yeh, Chi-Sen Chang
Wan-Tzu Lin, Yen-Chun Peng, Chung-Hsin Chang, Hong-Zen Yeh, Chi-Sen Chang, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan
Yi-Jun Liao, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Puli Branch of Taichung Veterans General Hospital, Nantou 54552, Taiwan
Ching-Heng Lin, Taichung Veteran General Hospital, Taichung 40705, Taiwan
Yen-Chun Peng, Hong-Zen Yeh, Faculty of Medicine, College of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
Author contributions: Lin WT and Liao YJ contributed equally to this work; Lin WT and Chang CS designed the study; Peng YC and Lin CH collected the clinical data; Chang CH and Lin CH analyzed and interpreted the data; Peng YC, Yeh HZ and Chang CS provided executive support for this study; Lin WZ and Liao YJ wrote the manuscript; and Chang CS provided critical revision of the manuscript for important intellectual content.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number: CE13152B-3).
Informed consent statement: The Institutional Review Board specifically waived the consent requirement, because the presented data are anonymized in Taiwan’s National Health Insurance Research Database, with no risk of identification.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Chi-Sen Chang, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan. changcs@vhgtc.gov.tw
Telephone: +886-4-23592525-2001 Fax: +886-4-23741331
Received: December 14, 2016
Peer-review started: December 16, 2016
First decision: January 10, 2017
Revised: February 12, 2017
Accepted: March 31, 2017
Article in press: March 31, 2017
Published online: May 21, 2017
Core Tip

Core tip: Selective serotonin reuptake inhibitor (SSRI) users were associated with a risk of subsequently diagnosed irritable bowel syndrome. The brain-gut axis may play a key role in this relationship. In clinical practice, physicians should pay attention to the gastrointestinal symptoms of patients with psychiatric disorders and SSRI use.